2016 Hematological Malignancies

First page Previous page 87 Next page Last page

HD21: GHSG Perspective BV in advanced stage HL

2 x BEACOPP esc

2 x BrECADD

Centrally reviewed PET

4x BrECADD

4x BEACOPP esc

End of therapy and residual nodes > 2.5 cm:

PET positiv: Rx PET negative: Follow up

Made with